biosim m2m BioSim M2M: Molecules to Medicine
- Coordinator
- Biosimulytics Limited, Ireland
- Runs
- 1 September 2023 to 28 February 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190181387
What the project is doing
In the project's own words, from its summary on CORDIS.
BioSimulytics has developed breakthrough technology combining quantum physics, computational chemistry, machine learning, and high-performance computing to boost the success rates of pharmaceutical R&D. The BioSimulytics invention (patent EP3948877A1), is being applied to crystal structure prediction (CSP) for determining the most stable crystal structure or polymorph of a drug compound, as well as the most stable binding poses in protein-ligand complexes.
Existing state-of-the-art techniques for polymorph analysis require long and painstaking experimentation by material scientists with uncertain results (<1% success rates). BioSim M2M will reduce the time to find the most stable crystal structures of a molecule from 3 months to 3 weeks and reduce candidate experiments from 400 to 40. As a result, BioSim M2M will contribute to the Pharmaceutical Strategy for Europe by helping to ensure that patients have access to high quality, effective, and safe medicines.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Biosimulytics Limited | Dublin | Ireland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI